Gilead Sciences, Inc. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored

Gilead vs Pharming: A Decade of Cost Efficiency Compared

__timestampGilead Sciences, Inc.Pharming Group N.V.
Wednesday, January 1, 201437880000004167274
Thursday, January 1, 201540060000005247851
Friday, January 1, 201642610000004925118
Sunday, January 1, 2017437100000014930297
Monday, January 1, 2018485300000025371768
Tuesday, January 1, 2019467500000023921274
Wednesday, January 1, 2020457200000025338236
Friday, January 1, 2021660100000020182966
Saturday, January 1, 2022565700000017562000
Sunday, January 1, 2023649800000025212000
Monday, January 1, 202428675800000
Loading chart...

Infusing magic into the data realm

Exploring Cost Efficiency: Gilead Sciences, Inc. vs Pharming Group N.V.

In the competitive landscape of the pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Gilead Sciences, Inc. and Pharming Group N.V. from 2014 to 2023. Over this period, Gilead Sciences consistently demonstrated a robust cost management strategy, with its cost of revenue peaking in 2021 at approximately 6.6 billion, a 74% increase from 2014. In contrast, Pharming Group N.V. showed a more modest growth, with its cost of revenue increasing by over 500% from 2014 to 2023, reaching around 25 million. This stark contrast highlights Gilead's significant scale and operational efficiency compared to Pharming's more gradual growth. As the industry evolves, these insights underscore the importance of strategic cost management in maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025